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Abstract
Background: Inactivation of the Fanconi anemia (FA) pathway through defects in one of 13 FA genes occurs at low 
frequency in various solid cancer entities among the general population. As FA pathway inactivation confers a distinct 
hypersensitivity towards DNA interstrand-crosslinking (ICL)-agents, FA defects represent rational targets for 
individualized therapeutic strategies. Except for pancreatic cancer, however, the prevalence of FA defects in 
gastrointestinal (GI) tumors has not yet been systematically explored.
Results: A panel of GI cancer cell lines was screened for FA pathway inactivation applying FANCD2 monoubiquitination 
and FANCD2/RAD51 nuclear focus formation and a newly identified FA pathway-deficient cell line was functionally 
characterized. The hepatocellular carcinoma (HCC) line HuH-7 was defective in FANCD2 monoubiquitination and 
FANCD2 nuclear focus formation but proficient in RAD51 focus formation. Gene complementation studies revealed 
that this proximal FA pathway inactivation was attributable to defective FANCC function in HuH-7 cells. Accordingly, a 
homozygous inactivating FANCC nonsense mutation (c.553C > T, p.R185X) was identified in HuH-7, resulting in partial 
transcriptional skipping of exon 6 and leading to the classic cellular FA hypersensitivity phenotype; HuH-7 cells 
exhibited a strongly reduced proliferation rate and a pronounced G2 cell cycle arrest at distinctly lower concentrations 
of ICL-agents than a panel of non-isogenic, FA pathway-proficient HCC cell lines. Upon retroviral transduction of HuH-7 
cells with FANCC cDNA, FA pathway functions were restored and ICL-hypersensitivity abrogated. Analyses of 18 surgical 
HCC specimens yielded no further examples for genetic or epigenetic inactivation of FANCC, FANCF, or FANCG in HCC, 
suggesting a low prevalence of proximal FA pathway inactivation in this tumor type.
Conclusions: As the majority of HCC are chemoresistant, assessment of FA pathway function in HCC could identify 
small subpopulations of patients expected to predictably benefit from individualized treatment protocols using ICL-
agents.
Background
Fanconi anemia (FA) is a rare recessive disorder, charac-
terized by congenital skeletal abnormalities, progressive
bone marrow failure and an increased cancer susceptibil-
ity [1]. The disease is caused by bi-allelic mutations in one
of 13 FA genes, all of which have now been identified [2].
The FA genes appear to act in a common pathway of
DNA damage signalling and DNA remodelling, distal
parts of which interact with regulators of cell cycle con-
trol and DNA repair, especially the repair of DNA inter-
strand-crosslinks.
There are three consecutive compartments of the FA
pathway [3]. The proximal compartment consists of eight
FA proteins (A, B, C, E, F , G, L, and M), which form a
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nuclear FA core complex upon activation. This complex
functions as an E3 ligase and mediates the monoubiquit-
ination of FANCD2 [4], which represents the central FA
pathway protein. FANCI also becomes monoubiquit-
inated during this process [5,6] and cooperates with
FANCD2 in the ID (FANCI/FANCD2) complex [7,8]. The
activated proteins of the ID complex subsequently co-
localize with proteins of the distal FA pathway compart-
ment (FANCD1/BRCA2, FANCN, and FANCJ) and with
other DNA-repair proteins such as RAD51 at sites of
DNA-damage. Cells having a defect in one of the proxi-
mal FA core complex genes are deficient in FANCD2/
FANCI monoubiquitination and FANCD2/FANCI
nuclear focus formation. Similarly, cells having a defect in
one of the distal FA pathway genes FANCD1 or FANCN
are deficient in RAD51 focus formation [8-12]. Cells with
a defect in one of the ID complex proteins lack the
respective protein and are defective in monoubiquitina-
tion of the other. Thus, inactivation of the FA pathway
can comprehensively be identified at the cellular level by
assays detecting FANCD2 monoubiquitination and
FANCD2/RAD51 focus formation.
FA pathway inactivation occurs sporadically in a variety
of tumor types of non-FA patients, suggesting a role of
the FA genes in tumor suppression or maintenance of
genomic stability among the general population. Distal
FA pathway inactivation via mutations in FANCD1
occurs in familial cases of breast (2-25%) [13] and ovarian
cancer (2-6%) [14], in familial cases of pancreatic cancer
(17%) [15] and in sporadic cancers of various tumor enti-
ties [16-18]. In comparison, genetic inactivation of the
proximal FA pathway appears to occur infrequently in
tumors among the general population and has, in terms
of GI cancers, yet only been reported in pancreatic can-
c e r ,  w h e r e  i t  w a s  a s s o c i a t e d  w i t h  r a r e  m u t a t i o n s  i n
FANCC or FANCG [19,20]. In addition, germline muta-
tions of FANCC might contribute to the tumorigenesis or
tumor progression of pancreatic cancer [20-22]. Finally,
epigenetic inactivation of the proximal FA pathway via
hypermethylation of FANCF has been reported in a vari-
ety of tumor entities [23-27], but its significance is not yet
well understood [28,29].
Unlike the setting in FA patients, FA pathway-deficient
tumors arising in patients of the general population har-
bor the FA gene defect exclusively in the tumor cells,
whereas stroma and all other non-malignant cells lack the
defect, thus representing a tumor-specific, absolute bio-
chemical difference [30]. As FA pathway-deficient cells
are hypersensitive to ICL-agents and PARP inhibitors, FA
pathway inactivation in tumors represents a promising
target for rational, genotype-based anticancer therapy
[31-38].
The prevalence of FA pathway defects has not yet been
systematically investigated in GI cancer. We assessed
proximal and distal FA pathway function in 48 cell lines
derived from gastric, pancreatic, colorectal, hepatocellu-
lar and cholangiocellular carcinomas applying assays for
FANCD2 monoubiquitination and FANCD2/RAD51
focus formation [39]. We newly identified a single cell
line, HuH-7, derived from a hepatocellular carcinoma
(HCC), which exhibited a proximal FA pathway defect,
ascribable to genetic FANCC  inactivation. When com-
pared to four other HCC cell lines, HuH-7 cells exhibited
an increased sensitivity towards ICL-agents, which was
reversible in these cells by genetic correction through
FANCC overexpression. Our data represent the first evi-
dence for genetic inactivation of the proximal FA pathway
in HCC and further support the assumption that genetic
inactivation of the proximal FA pathway is a rare event in
solid tumors among the general population.
Results
GI cancer cell line-screening identifies proximal FA 
pathway-deficiency in HuH-7 cells
48 gastrointestinal cancer cell lines (18 colorectal, 15 pan-
creatic, 8 gastric, 5 hepatocellular and 2 cholangiocellular
carcinomas) were screened for proximal and distal FA
pathway inactivation using FANCD2 immunoblotting,
FANCD2 and RAD51 nuclear focus formation (Fig. 1A,
Table 1). Results on FA pathway inactivation in pancre-
atic cancer cell lines have been previously reported and
were confirmed, including defective FANCD2 monou-
biquitination due to inactivating mutations in FANCG
and FANCC  in Hs766T and PL11 [20,22], respectively,
and defective RAD51 focus formation due to an inactivat-
ing FANCD1 mutation in Capan-1 [17]. Among all sam-
ples newly tested in the present study, we identified one
cell line without detectable FANCD2 monoubiquitina-
tion, the HCC line HuH-7 (Fig. 1A). To stimulate previ-
ously undetectable FANCD2 monoubiquitination, HuH-
7 cultures were pre-treated with mitomycin C (MMC) at
100 nM for 24 h. Despite such challenge, HuH-7 did not
display any trace of monoubiquitinated FANCD2. RKO
cells and derived clones harboring an engineered disrup-
tion of FANCG or FANCC were used as controls [36] (Fig.
1B). Likewise, no FANCD2 focus formation was observed
in HuH-7 after treatment with irradiation (IR) at 15 Gy 6
h prior to workup (Fig. 2A). In contrast, RAD51 focus
formation was readily detectable (Fig. 2B), confirming a
proximal FA pathway defect, whereas distal FA/BRCA
pathway function remained undisturbed.
Gene complementation studies reveal defective FANCC 
function in HuH-7 cells
To identify the FA gene responsible for proximal FA path-
way inactivation, HuH-7 cells were transduced with ret-
roviral constructs containing full-length cDNAs of
FANCA, FANCB, FANCC, FANCE, FANCF, FANCG orPalagyi et al. Molecular Cancer 2010, 9:127
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FANCL. FANCD2 monoubiquitination was assessed fol-
l o w i n g  e x p o s u r e  o f  t h e  t r a n s d u c e d  c u l t u r e s  t o  M M C .
Restoration of FANCD2 monoubiquitination was
observed only after complementation of HuH-7 cells with
the FANCC gene construct, whereas all other constructs
had no discernible effect (Fig. 3A). Consequently, exoge-
nous FANCC protein expression was confirmed in
FANCC-transduced HuH-7 cultures (Fig. 3B). To validate
functional FA pathway restoration upon transduction of
FANCC-cDNA, the cell cycle profiles of the transduced
cells were analyzed 48 h after treatment with MMC. The
pronounced G2 arrest, observed in non-FANCC-comple-
mented HuH-7 cells was restored to normal specifically
after transduction with FANCC, but not after transduc-
tion with any of the other FA or control constructs (Fig.
3C).
HuH-7 cells harbor a homozygous inactivating nonsense 
FANCC mutation in exon 6
Direct genomic sequencing of the coding exons and adja-
cent intron portions of FANCC  in HuH-7 revealed a
homo- or hemizygous inactivating nonsense mutation
c.553C > T, p.R185X in coding exon 6 (Fig. 3D). No other
sequence changes were identified.
Aberrant splicing leads to a truncated FANCC mRNA lacking 
exon 6 in HuH-7 cells
Using reverse-transcription PCR (RT-PCR) with primers
flanking a region that includes exon 6, we identified an
additional truncated FANCC  gene transcript in HuH-7
cells, which was not detectable in four HCC control cell
lines Chang, Hep3B, HepG2 and PLCPRF5 (Fig. 3E).
Upon gel-separation of the two RT-PCR products ampli-
fied from HuH-7 cDNA, direct sequencing confirmed
Table 1: FANCD2- and RAD51-nuclear focus formation in 48 GI cancer cell lines
Cell line Cancer type FANCD2 RAD51 Cell line Cancer type FANCD2 RAD51
AGS gastric + + L3.6pl pancreatic + +
AsPC-1 pancreatic + + LoVo colorectal + +
AZ-521 gastric + + LS1034 colorectal + +
BxPC-3 pancreatic + + LS513 colorectal + +
Caco-2 colorectal + + MIA PaCa-2 pancreatic + +
Capan-1 pancreatic + - MKN 45 gastric + +
Capan-2 pancreatic + + MKN 7 gastric + +
CFPAC-1 pancreatic + + NCI-N87 gastric + +
Chang hepatocellular + + PANC-1 pancreatic + +
CoGa 12 colorectal + + PL11 pancreatic - +
CoGa 5 colorectal + + PL3 pancreatic + +
CoGa 5L colorectal + + PL45 pancreatic + +
Colo 320 colorectal + + PL5 pancreatic + +
DLD-1 colorectal + + PL8 pancreatic + +
EGI-1 cholangiocellular + + PLCPRF5 hepatocellular + +
HCA-7 colorectal + + SNU-1 gastric + +
HCT 116 colorectal + + SNU-5 gastric + +
Hep3B hepatocellular + + SU.86.86 pancreatic + +
HepG2 hepatocellular + + SW48 colorectal + +
Hs766T pancreatic - + SW480 colorectal + +
HT-29 colorectal + + SW620 colorectal + +
HuH-7 hepatocellular - + SW948 colorectal + +
Isreco 1 colorectal + + TFK-1 cholangiocellu
lar
++
KATO III gastric + + WiDr colorectal + +
(+) detectable or (-) no detectable nuclear focus formation of FANCD2 or RAD51, respectively, in the indicated cell lines, 6 h after treatment 
with IR at 15 Gy. FA pathway-deficient cell lines are depicted in bold.Palagyi et al. Molecular Cancer 2010, 9:127
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that the correctly sized band represented the reference
FANCC  sequence except for the described c.553C > T
nonsense mutation, while the smaller band represented
the reference FANCC sequence lacking exon 6, leading to
a direct exon 5/7 junction (Fig. 3F).
HuH-7 cells are hypersensitive towards ICL-agents as 
compared to other HCC lines
Five HCC cell lines (Chang, Hep3B, HepG2, HuH-7 and
PLCPRF5) were treated either with common ICL-agents
(MMC, cisplatin and melphalan) or with common non-
ICL chemotherapeutics (5-fluorouracil (5-FU), etoposide
and doxorubicin). The sensitivity towards ICL-agents was
clearly dissimilar between the FA pathway-proficient cell
line panel and FANCC-deficient HuH-7 cells, with the
latter displaying a distinct hypersensitivity (inhibitory
concentration 50% (IC50) ratios [40] ranging between 3.4
to 18.6 as compared to the other HCC lines) (Fig. 4A,
upper panel). In contrast, treatment with non-ICL che-
motherapeutics did not distinguish HuH-7 as being most
sensitive (Fig. 4A, lower panel). The most consistent dif-
ference in ICL-agent sensitivity between the FA-pathway
proficient HCC cell lines and FANCC-deficient HuH-7
cells was observed using melphalan. This agent has previ-
ously been described to have the strongest effect among 8
ICL-agents tested in an isogenic FA cancer cell model
Figure 1 Detection of monoubiquitinated (L) and non-monoubiquitinated (S) FANCD2 protein to assess proximal FA pathway status in GI 
cell lines. (A) Immunoblotting to assess FANCD2 monoubiquitination in 48 tumor cell lines of pancreatic, colorectal, hepatocellular, gastric and cho-
langiocellular origin. Pancreatic cell lines were described previously, including the FA pathway-deficient cell lines Hs766T and PL11 (small arrows), and 
served as controls. The HCC cell line HuH-7 (big arrow) lacked spontaneous FANCD2 monoubiquitination. (B) FANCD2 immunoblotting of RKO cells 
(positive control), derived RKO FANCG -/- cells (negative control) and HuH-7 cells upon treatment with MMC at 100 nM for 24 h to stimulate potential 
previously undetectable FANCD2 monoubiquitination.
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Figure 2 FANCD2 and RAD51 nuclear focus formation to assess proximal and distal FA pathway function. (A) FANCD2 nuclear focus formation 
in RKO cells (positive control), derived RKO FANCG -/- cells (negative control), and a panel of five HCC cell lines including HuH-7, either treated with IR 
at 15 Gy for 6 h or left untreated. HuH-7 and RKO FANCG -/- cells lacked FANCD2 focus formation. (B) RAD51 nuclear focus formation in HuH-7 cells 
either treated with IR at 15 Gy for 6 h or left untreated.
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Figure 3 Gene complementation studies identifying an inactivating FANCC nonsense mutation in HuH-7. (A) FANCD2 monoubiquitination in 
FA pathway-proficient control HeLa cells and HuH-7 cells transduced with the indicated FA or control cDNA constructs. All cultures were exposed to 
MMC at 150 nM for 15 h. RAD50 served as loading control. Only transduction with FANCC restored FANCD2 monoubiquitination in HuH-7 cells. (B) 
FANCC immunoblotting using the indicated cell lysates. The nuclear protein p84 served as loading control. Only HuH-7 cells transduced with FANCC 
and FA pathway-proficient Hep3B control cells displayed FANCC protein. (C) Cell cycle distributions of HuH-7 cells transduced with the indicated FA 
or control cDNA constructs. All cultures were exposed to MMC at 33 nM for 15 h. Only transduction with FANCC abrogated the pronounced G2 cell 
cycle arrest upon MMC in HuH-7 cells. (D) Chromatogram of the homo- or hemizygous FANCC mutation (arrow) identified in HuH-7 cells. (E) RT-PCR 
using three different primer pairs amplifying a region from FANCC non-coding exon 1 to coding exon 5, or from coding exons 3 to 13, or from coding 
exons 7 to 13, respectively, using cDNA from five HCC cell lines. Only HuH-7 cells exhibited aberrant mRNA splicing lacking exon 6. (F) Direct sequenc-
ing of the two distinct RT-PCR products confirmed that the product having the correct size represented the reference FANCC sequence except for the 
c.553C > T mutation, whereas the shorter product lacked exon 6, exhibiting a direct exon 5/7 junction.
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[36]. Cell cycle distributions of the five HCC cell lines,
analyzed upon treatment with MMC for 48 h, revealed a
pronounced G2 arrest (defined here by a fraction of >40%
of cells in G2) [36] at low MMC concentrations (25 nM)
only in HuH-7 cells (Fig. 4B), whereas a similar G2 arrest
was achieved in a dose-dependent manner in all HCC cell
lines except PLCPRF5 at higher MMC concentrations (50
to 100 nM) (Fig. 4C).
ICL-hypersensitivity of HuH-7 cells is abrogated upon 
exogenous FANCC expression
HuH-7 cells were stably transduced using retroviral con-
structs containing either full length FANCC-cDNA
(HuH-7/FANCC), tagged with recombinant influenza
virus hemagglutinin (HA-tag), or empty vector (HuH-7/
ev). Consecutively, exogenous FANCC  expression was
confirmed (Fig. 5A). HuH-7/FANCC cells, but not paren-
tal HuH-7 or HuH-7/ev control cells, displayed restored
proximal FA-pathway function as demonstrated by con-
stitutive and MMC-inducible [41] FANCD2 monoubiq-
uitination (Fig. 5B) as well as proficiency in FANCD2
nuclear focus formation (Fig. 5C). Most importantly, sen-
sitivity towards ICL-agents was significantly reduced in
HuH-7/FANCC cells as compared to parental HuH-7 and
HuH-7/ev control cells (Fig. 5D, upper panel), whereas
sensitivity towards non-ICL-chemotherapeutics
remained virtually unchanged (Fig. 5D, lower panel).
No evidence for inactivation of FANCC, FANCG or FANCF in 
18 HCC tissue specimens
To assess the prevalence of proximal FA pathway inacti-
vation in HCC, 18 surgical HCC tissue specimens were
analyzed for inactivation of FANCC, FANCF or FANCG
through screening for genetic mutations, epigenetic
silencing through CpG hypermethylation or lack of
mRNA-expression. On the genetic level, direct sequenc-
ing of the complete coding sequences of FANCC, FANCF
and FANCG in 18 HCC samples identified a single not
previously reported, heterozygous, synonymous FANCC
sequence variant (c.813G > A) and two heterozygous,
non-synonymous  FANCG  variants (c.20C > T, p.S7F;
c.643C > A, p.Q215K) (Fig. 6A). No other sequence vari-
ants, especially no inactivating point mutations, small
deletions, insertions, large intragenic deletions or com-
plete homozygous gene deletions, were found. On the
epigenetic level, HpaII-restriction assays yielded no evi-
dence for FANCC-,  FANCF-  or  FANCG-silencing
through CpG hypermethylation (Fig. 6B) and consis-
tently, FANCC-, FANCF- and FANCG-mRNA was detect-
able in all 18 HCC samples (Fig. 6C).
Discussion
We report here the identification and functional charac-
terization of an inactivating nonsense FANCC mutation
in the HCC cell line HuH-7. This cell line was established
from a well-differentiated HCC of a 57 year-old Japanese
male patient [42], displays an aneuploid phenotype with
an average number of 60 chromosomes, and is negative
for HBV and HCV [43,44]. To our knowledge, this is the
first evidence of genetic inactivation of the proximal FA
pathway in a GI tumor entity other than pancreatic can-
cer.
The identified FANCC nonsense mutation c.553C > T,
p.R185X in HuH-7 represents a known FA mutation, first
described by Gibson et al. [45]. Interestingly, non-splice
site nonsense mutations can cause exon-skipping
through aberrant splicing [46], and accordingly, the
c.553C > T mutation has been reported to cause partial
transcriptional skipping of exon 6 of FANCC  in an FA
patient [45], a mechanism confirmed for HuH-7 in our
study.
Unfortunately, no matched non-malignant tissue is
available for HuH-7, precluding definitive genomic copy
number analyses in regard to whether the identified
FANCC  mutation represents a homo- or hemizygous
mutation in this cell line. However, according to copy
number analyses by the Sanger Institute (Cambridge, UK)
using high-density single nucleotide polymorphism
(SNP) arrays (SNP 6.0) [47], HuH-7 harbors three nearly
identical copies of the chromosomal arm 9q, where
FANCC  is located at 9q22.3, as evidenced by virtually
exclusive homozygosity of all SNPs assessed on 9q.
According to proposed evaluation models for the identifi-
cation of LOH events where no matching normal tissue is
available, these data are strongly suggestive (although not
definitely evidentiary) of allelic loss of one copy of chro-
mosome 9q including the non-mutated FANCC allele in
the original tumor (or its precursor cells), followed by
repeated duplication of the remaining chromosome 9q,
including the mutated FANCC  allele, later on [48-50].
Typical recurrent numerical chromosomal aberrations in
HCC include losses on 1p, 4q, 8p, 13q, 16q, and 17p and
gains on 1q, 8q, 16p and 20q [51]. Although chromosome
9 is rarely clonally altered on the cytogenetic level in
HCC, LOH has been reported for several regions on
chromosome 9 including the loci of the FANCC (9q22.3)
and the FANCG (9p13) genes [52].
FA pathway defects in tumors require bi-allelic inacti-
vation of one of at least 13 FA genes. On the one hand,
these bi-allelic mutations could both be inherited, as
applies to tumors occurring in FA-patients. On the other
hand, mono-allelic germline mutations of distal FA path-
way genes, such as FANCD1, FANCN or FANCJ, confer
low to medium penetrance susceptibility for breast/ovar-
ian cancer [12,13,53] and, as applies to FANCD1  and
FANCN, also for pancreatic cancer [15,54-57]. In addi-
tion, inherited mono-allelic mutations of proximal FA
pathway genes have been associated with the predisposi-Palagyi et al. Molecular Cancer 2010, 9:127
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Figure 4 Hypersensitivity of HuH-7 cells specifically towards ICL-agents. (A) Cell proliferation assays to compare the sensitivity of five HCC cell 
lines towards ICL- and non-ICL-chemotherapeutic agents. HuH-7 cells were hypersensitive towards treatment with any of three ICL-agents as com-
pared to four FA pathway-proficient HCC lines (upper panel: MMC, cisplatin, melphalan), with IC50 ratios ranging from 3.4- to 18.6-fold (arrows, indi-
cated in red), but not towards any of three non-ICL-agents (lower panel: 5-FU, doxorubicin, etoposide). Error bars represent SEM of three independent 
experiments. (B) Flow cytometric cell cycle profiles of five HCC cell lines 48 h after treatment with MMC at the indicated concentrations. A pronounced 
G2 arrest (defined here as a cell fraction of >40% in G2 [36]) at low-dose MMC (25 nM) was observed only in HuH-7 cells. (C) Graphic representation 
of the cell cycle distributions from a representative experiment displaying the fraction of cells in G1, S or G2 at the indicated MMC concentrations for 
the indicated HCC cell lines. Arrows indicate the lowest dose at which a G2 arrest of more than 40% of the cells was observed.
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Figure 5 Abrogation of the ICL-hypersensitivity phenotype in HuH-7 through exogenous FANCC expression. (A) Immunoblotting for the de-
tection of FANCC-HA in parental HuH-7 cells (HuH-7) and HuH-7-derived clones retrovirally transduced with either empty vector-pMSCV (HuH-7/ev) 
or with pMSCV-FANCC (HuH-7/FANCC). HeLa cells transduced with pMSCV-FANCC were used as controls. CULLIN-1 served as loading control. FANCC-
HA was detectable only in HuH-7/FANCC and control HeLa/FANCC cells. (B) FANCD2 monoubiquitination in parental HuH-7, HuH-7/ev and HuH-7/
FANCC cells, respectively, either treated with MMC at 100 nM for 24 h or left untreated. RKO cells and derived RKO FANCC-/-/- cells were used as con-
trols. β-ACTIN served as loading control. Monoubiquitinated FANCD2 was detectable only in HuH-7/FANCC and parental RKO control cells and was 
inducible upon MMC-treatment, confirming correction of proximal FA pathway function through exogenous FANCC expression in HuH-7. (C) FANCD2 
nuclear focus formation in parental HuH-7, HuH-7/ev and HuH-7/FANCC cells either treated with IR at 15 Gy for 6 h or left untreated. FANCD2 focus 
formation was detectable only in HuH-7/FANCC cells. (D) Cell proliferation assays to compare the sensitivity of parental HuH-7, HuH-7/ev and HuH-7/
FANCC cells towards ICL- and non-ICL-chemotherapeutic agents. HuH-7/FANCC cells were less sensitive towards treatment with ICL-agents than pa-
rental and HuH-7/ev control cells (upper panel: MMC, cisplatin, melphalan), with IC50 ratios ranging from 3.4- to 4.2-fold (arrows, indicated in red), 
whereas sensitivity towards non-ICL-agents (lower panel: 5-FU, doxorubicin, etoposide) remained virtually unchanged. Error bars represent SEM of 
three independent experiments.
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tion for or the accelerated development of certain tumors
[21,54,55,58]. In particular, germline mutations of
FANCC have been described in pancreatic cancer, associ-
ated with LOH in the tumor [21,22]. However, germline
and somatic changes in FANCC and FANCG may have
comparatively low penetrance for pancreatic cancer [55],
which is supported by studies investigating germline
mutations of upstream FA pathway genes in sporadic, yet
FA-typical tumors among the general population [59].
Nevertheless, as the FANCC mutation in HuH-7 reported
in our study represents an established FA mutation and
was therefore most likely present in the germline of the
patient in mono-allelic form, our data might indicate an
increased risk for the development of HCC in individuals
of the general population harboring this or other FANCC
mutations.
The occurrence of an FA-associated FANCC mutation
in HCC could also denote a tissue-specific susceptibility
for the development of HCC in FA patients; The majority
of solid malignancies seen in FA patients consists of head
and neck or gynaecologic carcinomas (5.3%), as reported
in a large meta-analysis of 1300 cases [60], but also 2.8%
of all FA patients developed liver tumors. These tumors
manifested at a significantly younger age than other solid
malignancies (median age: 13 years for liver tumors as
compared to 26 years for other solid malignancies). In
fact, the cumulative probability of liver tumors in FA
patients has been estimated to be 46% by age 50 [60].
However, the significance of these data regarding a
potential liver-specific cancer susceptibility of FA
patients is complicated by the observation that many liver
tumors do not proceed to malignancy during the life span
of FA patients [60,61]. In addition, there appears to be a
strong association between androgen therapy, which is
frequently used for the treatment of bone marrow failure
in FA, and the occurrence of liver tumors [60-63]. Never-
theless, HCC represented the majority (58%) of tumors of
36 FA patients with androgen-related liver tumors in one
study [61]. Thus, the association of FA with HCC could
be attributable both to the primary tumorigenic effects of
Figure 6 Screening of 18 HCC tissues for inactivation of FANCC, FANCF or FANCG. (A) Chromatograms displaying the identified heterozygous 
sequence variants (arrows) in FANCC and FANCG. (B) PCR-based HpaII-restriction assays to determine methylation status of FANCC, FANCF and FANCG 
in 18 HCC tissues. The corresponding CpG island-containing regions were PCR-amplified before and after digestion using the indicated enzymes: U 
= undigested, H = HpaII digestion, M = MspI digestion. Universal methylated and unmethylated human DNA (hDNA) was used as controls. No hyper-
methylation of FANCC, FANCF or FANCG was detected in any of the 18 HCC samples. (C) RT-PCR to assess mRNA-expression of FANCC, FANCF and 
FANCG in 18 HCC tissues. All samples expressed FANCC-, FANCF- and FANCG-mRNA.
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FA pathway inactivation in hepatocytes, as well as to
potential secondary, amplifying or accelerating effects of
androgen therapy in FA patients.
We demonstrated that HCC cells having an inactivated
FA pathway display the classic cellular FA phenotype,
including a specific hypersensitivity towards ICL-agents,
illustrated in HuH-7 by a pronounced cell cycle arrest in
G2 upon treatment with MMC at low concentrations and
a strongly decreased proliferation rate as compared to a
panel of non-isogenic HCC lines. Importantly, this ICL-
hypersensitivity phenotype was reversed using an
isogenic HuH-7 model of exogenous FANCC expression,
confirming that ICL-hypersensitivity in these cells was
attributable specifically to inactivation of FANCC. Of
note however, IC50-ratios between FANCC-deficient and
FANCC-proficient cells were partly smaller in the
isogenic model than could have been expected from our
results using the non-isogenic model. This observation
could be attributable to FA pathway-independent ICL-
sensitivity differences among the non-isogenic HCC cell
lines, but could also provide further support for our pre-
vious hypothesis that constitutive exogenous FANCC
over-expression does not completely substitute for physi-
ologically regulated, endogenous FANCC  expression
[37,38].
It is well established that systemic chemotherapy lacks
effectiveness in unselected HCC patients [64,65] and
HCC are therefore considered largely chemoresistant, at
least partially explaining the poor prognosis of this tumor
entity [66]. Accordingly, guidelines are currently lacking
also regarding the choice of chemotherapeutic agent to
use in transarterial chemoembolization (TACE), one of
the major treatment modalities for non-surgical patients
at advanced HCC stages [67]. Our data indicate that non-
FA patients having a FA-deficient HCC might predictably
benefit from treatment using ICL-agents. Consequently,
assessment of FA pathway function in HCC could facili-
tate individualized therapeutic approaches, using geno-
type-based patient stratification in regard to both
systemic chemotherapy and TACE.
To get an estimate of the prevalence of FANCC inacti-
vation in HCC, we sequenced cDNA derived from 18 sur-
gical HCC tissue specimens to screen for genetic FANCC
inactivation. We further screened these samples for
hypermethylation of the FANCC promoter region and for
lack of FANCC mRNA expression, as epigenetic FANCC
inactivation has previously been reported in acute leu-
kaemia and breast cancer [68,69]. Additionally, we
included  FANCG  and  FANCF  in these analyses, as
FANCG  represents another proximal FA gene that has
been described to be mutated in GI cancer, specifically in
pancreatic cancer [20,22], while FANCF  has been
reported to be epigenetically inactivated in various tumor
types [23-25,27]. On the genetic level, we found no fur-
ther inactivating alterations, especially no evidence for
complete homozygous gene deletions, inactivating point
mutations, small deletions or insertions, in FANCC,
FANCG  or  FANCF, respectively. The detected FANCG
variant c.20C > T, p.S7F has been reported in an FA
patient of the complementation group G in addition to
pathogenic FANCG mutations [70]. There is no informa-
tion available on the nature of the c.643C > A, p.Q215K
variant in FANCG. However, LOH or a second sequence
variant was not detected in that tumor either. Addition-
ally, since only two to three overlapping PCR reactions
were used to amplify the complete coding sequences of
FANCC, FANCG and FANCF, respectively, most poten-
tial large intragenic deletions would have been detected.
However, this mechanism of proximal FA gene inactiva-
tion occurs almost exclusively in FANCA, whereas it
appears to be extremely rare in FANCC and has not at all
been described in FANCG [20,71-73]. On the epigenetic
level, we found no evidence for hypermethylation of
FANCC,  FANCG  or  FANCF  in any of the 18 samples.
Consistently,  FANCC,  FANCG  and  FANCF  were
expressed in all samples on the mRNA level.
Our negative screening results for proximal FA pathway
inactivation in HCC were not unexpected, as a hypotheti-
cal high prevalence should have become evident earlier
during clinical trials - manifesting as a selective chemo-
sensitivity of the majority of HCC towards ICL-agents.
Nevertheless, the lack of FA mutations in 18 HCC does
not rule out rare occurrences of proximal FA pathway
inactivation in HCC and is consistent with previous
reports on the low prevalence of proximal FA pathway
inactivation in various tumor entities among the general
population [20-22,26,29,68]. Future studies applying a
higher sample number are required to definitely deter-
mine the prevalence of FA pathway inactivation in HCC.
Conclusions
In summary, we identified a HCC cell line harboring an
inactivating mutation of the FANCC  gene, specifically
causing proximal FA pathway inactivation and the classic
cellular ICL-hypersensitivity phenotype. Assessment of
FA pathway function in HCC could thus represent a novel
approach to identify small subgroups of HCC patients
expected to predictably benefit from individualized treat-
ment protocols using ICL-agents. However, as proximal
FA pathway inactivation occurs at low frequency in HCC
and other tumors among the general population, the
development of rapid, economic and clinically applicable
screening tests for proximal FA pathway inactivation,
particularly in primary tumor tissues, remains an indis-
pensable requirement to facilitate future clinical studies
[38].Palagyi et al. Molecular Cancer 2010, 9:127
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Materials and methods
Cell lines, culture conditions and HCC tissue samples
Cell lines PL3, PL5, PL8, PL11 and PL45 were kindly pro-
vided by S.E. Kern (Johns Hopkins University, Baltimore,
Maryland). Cell lines AZ-521, CoGa-5, CoGa-5L, Coga-
12, HCA-7, Isreco 1, MKN7, MKN45, NCl-N87 and
L3.6pl were kindly donated by C.J. Bruns, M. Gerhard,
F.T. Kolligs and M. Ogris (Technical University and Lud-
wig-Maximilians-University, Munich, Germany). The
remaining cell lines were purchased from the European
Collection of Cell Cultures (Sigma-Aldrich, Munich, Ger-
many) or the American Type Culture Collection (LGC
Standards, Wesel, Germany). RKO cells harboring an
engineered disruption of the FANCG  or  FANCC  gene
have been described [36]. Cells were grown in DMEM
supplemented with 10% fetal calf serum, L-glutamine and
penicillin/streptomycin (PAA, Cölbe, Germany). The 18
HCC tissue samples were a kind gift of the Human Tissue
and Cell Research-Trust (HTCR, Regensburg, Germany)
and originated from HCCs that where surgically removed
at the Ludwig-Maximilians-University (Munich, Ger-
many).
Immunoblotting
Cells were treated with MMC (Sigma) at 100 nM for 24 h
or left untreated. Consecutively, cells were lysed and pro-
tein extracts boiled and loaded on 6% polyacrylamide
gels. After electrophoresis, proteins were transferred to
PVDF membranes, which were blocked for 1 h in TBS-
Triton X-100/2% milk before the primary antibody was
applied overnight at 4°C (1:1000; anti-FANCD2 H-300,
Santa Cruz Biotechnology, Heidelberg, Germany; anti-
FANCC ab5065, Abcam, Cambridge, UK). HA-tagged
FANCC was detected using an anti-HA antibody (1:1000;
12CA5, Santa Cruz). Antibodies directed against anti-
RAD50 (1:5000; 13B3, GeneTex, San Antonio, TX), anti-
p84 (1:1000; ab487, Abcam), anti-CUL1 (1:1000; 2H4C9,
Invitrogen, Karlsruhe, Germany) or anti-β-ACTIN
(1:10.000; AC-15, Sigma) served as loading controls. The
membranes were washed and stained with anti-rabbit or
anti-mouse HRP-conjugated antibodies (1:2000 to
1:10.000; GE Healthcare, Freiburg, Germany). Enhanced
chemo-luminescence was elicited using SuperSignal
West Pico substrate (Thermo Scientific, Schwerte, Ger-
many) according to the manufacturer's instructions.
Nuclear focus formation assays
Experiments were performed as described before [74]. In
brief, cells were grown on coverslips until ~80% conflu-
ency and were exposed to ionizing γ-radiation (IR) at 15
Gy using a cesium-137 irradiator. After incubation for 6
h, the cells were fixed using 3.7% formaldehyde and -20°C
methanol. The cells were permeabilized using Triton X-
100 and incubated in blocking buffer (PBS +2% bovine
serum albumin +0.5% Triton X-100) for 30 min. Consec-
utively, the cells were labelled using antibodies against
FANCD2 (FI-17) or RAD51 (H-92) (Santa Cruz), respec-
tively, for 2 h at room temperature. After washing, Alexa
488 goat anti-mouse or anti-rabbit antibody (Invitrogen)
was applied for 1.5 h. Nuclei were counterstained using
Hoechst 33342 (Roche Diagnostics, Mannheim, Ger-
many), mounted and analyzed using a fluorescence
microscope and Axiovision Software (Carl Zeiss AG;
Oberkochen, Germany). The settings were kept identical
for all samples.
Gene complementation studies
For FA complementation group determination, the cell
line HuH-7 was transduced with retroviral constructs
containing full-length cDNAs of FANCA,  FANCB,
FANCC, FANCE, FANCF, FANCG  or FANCL  and ana-
lyzed for cell cycle arrest upon treatment with MMC and
for restoration of FANCD2 monoubiquitination, as previ-
ously described [26]. For isogenic studies, HuH-7 cells
were stably transduced with either HA-tagged pMSCV-
FANCC (HuH-7/FANCC) or the corresponding pMSCV
empty control vector (HuH-7/ev).
gDNA sequencing
High molecular weight genomic DNA was prepared
using a salting-out technique. Amplification of the
FANCC  exons was performed using published primer
sets [75]. PCR products were purified using the GFX PCR
DNA and Gel Band Purification kit (GE Healthcare).
DNA sequencing of PCR products was performed using
ABI-PRISM big-dye terminator chemistry on the ABI 310
instrument (Applied Biosystems, Darmstadt, Germany).
mRNA expression analyses and cDNA sequencing
Total RNA was extracted from surgical HCC tissues or
cell lines using the NucleoSpin RNAII-Kit (Macherey-
Nagel, Düren, Germany). RNA was reverse-transcribed
using SuperScriptII reverse transcriptase (Invitrogen)
and cDNA synthesized. Aberrant splicing of FANCC was
determined by RT-PCR using the following primer pairs:
Fwd 5'-ACTGCCCAAACTGCTGAAG-3' and Rev 5'-
GTTCAGACGCTAATGATAAAACCA-3' (spanning the
first non-coding exon to coding exon 5), Fwd 5'-TTCTG-
GACAATCAAAACTTAACTCC-3' and Rev 5'-GCT-
GCTGCTTCTGGACATT-3' (spanning the coding exons
3 to 13), Fwd 5'-GTAGTCTG CCTCTGGCTTCG-3' and
Rev 5'-TTGAGGAGAAGGTGCCTGAT-3' (spanning the
coding exons 7 to 13). Expression of FANCC, FANCF and
FANCG mRNA was validated by RT-PCR as described
previously [76]. For sequencing of the complete coding
regions of FANCC, FANCF and FANCG, respectively, the
corresponding cDNAs were amplified in two (FANCF) or
three (FANCC and FANCG) overlapping PCR reactions
(primer sets available on request). Amplified productsPalagyi et al. Molecular Cancer 2010, 9:127
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were sequenced using an ABI-Prism 3100-Avant
Sequencer (Applied Biosystems) and sequence changes
confirmed at the genomic level by gDNA sequencing.
Reference genomic and cDNA sequences of the FA genes
are available in the Fanconi Anemia Mutation Database
[77].
Cell proliferation assays
The assays were performed over a broad range of concen-
trations covering 100% to 0% cell survival. 1,500-2,000
cells/well were plated in 96-well plates, allowed to adhere,
and treated. Following incubation for 6 d, the cells were
washed, lysed in 100 μl H2O, and 0.5% Picogreen (Molec-
ular Probes, Invitrogen) was added. Fluorescence was
measured (Cytofluor Series 4000, Applied Biosystems)
a n d  g r o w t h  i n h i b i t i o n  c a l c u l a t e d  a s  c o m p a r e d  t o  t h e
untreated control samples. Three independent experi-
ments were performed per agent, with each data point
reflecting triplicate wells. Error bars represent standard
error of the mean (SEM) from three experiments.
Cell cycle analyses
Cells were seeded in 12-well plates and treated in dupli-
cate for 48 h using various MMC concentrations (ranging
from 25 to 200 nM) or were left untreated. The cells were
fixed, stained with propidium iodide, and the DNA con-
tent per cell was measured using flow cytometry (FACS-
Calibur, Becton Dickinson, Heidelberg, Germany). The
data were analyzed using CELLQuest Pro software (Bec-
ton Dickinson). Alternatively, unfixed cells were stained
with DAPI at a final concentration of 1 μg/ml in a buffer
containing 154 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2,
0.1 M TRIS, 0.2% BSA, and 0.1% NP40 for 30 min in the
dark. Univariate flow histograms were recorded on an
analytical, triple-laser equipped flow cytometer (LSRII,
Becton Dickinson) using UV excitation of the DAPI dye.
The resulting cell cycle distributions reflecting cellular
DNA content were quantified using the MPLUS AV soft-
ware package (Phoenix Flow Systems, San Diego, CA).
HpaII restriction enzyme methylation analysis
PCR-based HpaII-restriction assays were performed as
described previously [23]. Transcriptional silencing
through CpG hypermethylation was analyzed using pub-
lished primer sets for FANCF  [23] and FANCC  [69],
respectively. Primers used for FANCG were 5'-GAGTG-
CAATGGCACGATG-3' (forward) and 5'-GCATGCTG-
GGAGTCGTAGTA-3' (reverse). CpGenome universal
methylated or unmethylated DNA (Chemicon - Milli-
pore, Schwalbach am Taunus, Germany), respectively,
were used as controls.
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